News Column

Gen9 Launches New Product to Enable Pathway and Genome Building

August 5, 2014

By a News Reporter-Staff News Editor at Life Science Weekly -- Gen9, Inc., the pioneer in the development of scalable technologies for synthesizing and assembling DNA, announced the commercial launch of GeneByte Plus™ DNA constructs, synthesized at lengths ranging from 3,000 to 10,000 base pairs. This new capacity extends the company's product portfolio, which also includes synthesized DNA below 3,000 base pairs in length (see also Gen9, Inc.).

Just as chemical engineering transformed 20th century manufacturing with cutting-edge building blocks that led to important new materials such as nylon and plastic, engineered DNA will provide the next-generation building blocks needed for environmentally responsible, efficient manufacturing in the 21st century. High-accuracy constructs in the multi-kilobase range will enable scientists in biology and other industrial fields to study the behavior of full genes, metabolic pathways, distant genetic elements, genomes, and other aspects of DNA that cannot currently be interrogated with shorter synthetic DNA fragments.

"With GeneByte Plus DNA constructs, we are now producing and shipping clonal, sequence-perfect constructs up to 10 Kb in length from our facility in Cambridge, Massachusetts, and have the capacity in-house to meet the rapidly increasing global demand for DNA," said Kevin Munnelly, President and Chief Executive Officer of Gen9. "Our high-throughput, chip-based manufacturing process is already facilitating the expansion of synthetic biology to many customers in industries that couldn't previously use it due to cost and limited in-house molecular biology expertise."

Gen9 is the first next-generation gene synthesis company producing synthetic DNA constructs used in numerous applications, including antibody, peptide, and enzyme engineering; gene and pathway construction; and genome assembly. In addition to GeneByte Plus, Gen9 is currently manufacturing and shipping double-stranded GeneBit™ and GeneByte™ DNA constructs, or gene fragments from 500 to 3,000 base pairs long. The company's innovative BioFab® platform has the capacity to generate tens of thousands of synthetic constructs per year in just a few square feet of laboratory space. All of Gen9's products are sequence verified and sent in clonal form, either in a vector or as linear DNA.

More information can be found at About Gen9 Gen9 is synthesizing the future with its next-generation DNA manufacturing technologies. Founded by pioneers in the field of synthetic biology, Gen9 supplies synthetic DNA constructs to customers in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Through high-profile collaborations and extensive internal research and development, Gen9 is powering the synthetic biology revolution from its headquarters in Cambridge, Massachusetts, and can be found online at Gen9, GeneBit, GeneByte and BioFab are trademarks or registered trademarks of Gen9, Inc.

Keywords for this news article include: Gen9 Inc., Technology, Engineering, DNA Research.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Life Science Weekly

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters